Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 205

1.

Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.

Ciaffi L, Cavassini M, Genne D, Delhumeau C, Spycher Elbes R, Hill A, Wandeler G, Fehr J, Stoeckle M, Schmid P, Hirschel B, Montecucco F, Calmy A; Swiss HIV Cohort Study..

Eur J Clin Invest. 2015 Jul;45(7):720-30. doi: 10.1111/eci.12464.

PMID:
25989829
2.

Treatment of Clostridium difficile infection in a French university hospital.

Khanafer N, Blais L, Barbut F, Hirschel B, Vanhems P.

Scand J Gastroenterol. 2015;50(10):1253-60. doi: 10.3109/00365521.2015.1033746. Epub 2015 Apr 15.

PMID:
25877477
3.

Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study.

Carballo D, Delhumeau C, Carballo S, Bähler C, Radovanovic D, Hirschel B, Clerc O, Bernasconi E, Fasel D, Schmid P, Cusini A, Fehr J, Erne P, Keller PF, Ledergerber B, Calmy A; Swiss HIV Cohort Study and AMIS registry..

AIDS Res Ther. 2015 Feb 22;12:4. doi: 10.1186/s12981-015-0045-z. eCollection 2015.

4.

Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence.

Fätkenheuer G, Hirschel B, Harbarth S.

Lancet. 2015 Mar 21;385(9973):1146-9. doi: 10.1016/S0140-6736(14)60660-7. Epub 2014 Aug 20. No abstract available.

PMID:
25150745
5.

HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.

Bunupuradah T, Bowonwattanuwong C, Jirajariyavej S, Munsakul W, Klinbuayaem V, Sophonphan J, Mahanontharit A, Hirschel B, Ruxrungtham K, Ananworanich J; HIV STAR Study team..

Antivir Ther. 2014;19(6):579-86. doi: 10.3851/IMP2737. Epub 2014 Jan 24.

PMID:
24464590
6.

Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field.

Granziera C, Daducci A, Simioni S, Cavassini M, Roche A, Meskaldji D, Kober T, Metral M, Calmy A, Helms G, Hirschel B, Lazeyras F, Meuli R, Krueger G, Du Pasquier RA.

PLoS One. 2013 Sep 10;8(9):e72547. doi: 10.1371/journal.pone.0072547. eCollection 2013.

7.

The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.

Beerenwinkel N, Montazeri H, Schuhmacher H, Knupfer P, von Wyl V, Furrer H, Battegay M, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Yerly S, Böni J, Klimkait T, Cellerai C, Günthard HF; Swiss HIV Cohort Study..

PLoS Comput Biol. 2013;9(8):e1003203. doi: 10.1371/journal.pcbi.1003203. Epub 2013 Aug 29.

8.

Capnocytophaga canimorsus prosthetic aortitis in an HIV-positive woman.

Rougemont M, Ratib O, Wintsch J, Schrenzel J, Hirschel B.

J Clin Microbiol. 2013 Aug;51(8):2769-71. doi: 10.1128/JCM.00321-13. Epub 2013 May 22.

9.

A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.

Aouri M, Calmy A, Hirschel B, Telenti A, Buclin T, Cavassini M, Rauch A, Decosterd LA.

J Mass Spectrom. 2013 May;48(5):616-25. doi: 10.1002/jms.3200.

PMID:
23674286
10.

The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study.

Wang Q, Young J, Bernasconi E, Cavassini M, Vernazza P, Hirschel B, Weber R, Furrer H, Stoeckle M, Bucher HC, Fux C; Swiss HIV Cohort Study..

Antivir Ther. 2013;18(3):337-44. doi: 10.3851/IMP2372. Epub 2012 Sep 12.

PMID:
23603864
11.

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.

Simioni S, Cavassini M, Annoni JM, Métral M, Iglesias K, Rimbault Abraham A, Jilek S, Calmy A, Müller H, Fayet-Mello A, Giacobini E, Hirschel B, Du Pasquier RA.

Neurology. 2013 Feb 5;80(6):553-60. doi: 10.1212/WNL.0b013e3182815497. Epub 2013 Jan 23.

PMID:
23345635
12.

A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.

Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K; HIV STAR Study Group..

Antivir Ther. 2012;17(7):1351-61. doi: 10.3851/IMP2443. Epub 2012 Jul 2. Erratum in: Antivir Ther. 2012;17(7):1389-90.

PMID:
23075703
13.

Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections.

Ambrosioni J, Junier T, Delhumeau C, Calmy A, Hirschel B, Zdobnov E, Kaiser L, Yerly S; Swiss HIV Cohort Study..

AIDS. 2012 Oct 23;26(16):2079-86. doi: 10.1097/QAD.0b013e32835805b6.

PMID:
23052354
14.

Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.

Bunupuradah T, Chetchotisakd P, Jirajariyavej S, Valcour V, Bowonwattanuwong C, Munsakul W, Klinbuayaem V, Prasithsirikul W, Sophonphan J, Mahanontharit A, Hirschel B, Bhakeecheep S, Ruxrungtham K, Ananworanich J; HIV STAR Study Group..

J Neurovirol. 2012 Dec;18(6):479-87. doi: 10.1007/s13365-012-0127-9. Epub 2012 Sep 20.

PMID:
22993101
15.

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.

Elzi L, Erb S, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M; Swiss HIV Cohort Study..

Arch Intern Med. 2012 Sep 24;172(17):1313-21. doi: 10.1001/archinternmed.2012.3216.

PMID:
22892835
16.

Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine.

Siegrist CA, van Delden C, Bel M, Combescure C, Delhumeau C, Cavassini M, Clerc O, Meier S, Hadaya K, Soccal PM, Yerly S, Kaiser L, Hirschel B, Calmy A; H1N1 Study Group.; Swiss HIV Cohort Study (SHCS)..

PLoS One. 2012;7(7):e40428. doi: 10.1371/journal.pone.0040428. Epub 2012 Jul 27.

17.

Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia.

Aouri M, Decosterd LA, Buclin T, Hirschel B, Calmy A, Livio F.

AIDS. 2012 Mar 27;26(6):776-8. doi: 10.1097/QAD.0b013e328351f662. No abstract available.

PMID:
22436541
18.

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, Yukl S, Greene WC, Kovari H, Rauch A, Fellay J, Battegay M, Hirschel B, Witteck A, Bernasconi E, Ledergerber B, Günthard HF, Wong JK; Swiss HIV Cohort Study..

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3035-40. doi: 10.1073/pnas.1111573109. Epub 2012 Feb 6.

19.

Kidney light chain disease in patients with the acquired immunodeficiency syndrome.

Villaverde RV, Darioli V, Hirschel B, McKee TA, Lobrinus JA, Moll S.

Clin Kidney J. 2012 Feb;5(1):59-62. doi: 10.1093/ckj/sfr176.

20.

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Glass TR, Rotger M, Telenti A, Decosterd L, Csajka C, Bucher HC, Günthard HF, Rickenbach M, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Marzolini C; Swiss HIV Cohort Study..

PLoS One. 2012;7(1):e29186. doi: 10.1371/journal.pone.0029186. Epub 2012 Jan 3.

Supplemental Content

Loading ...
Support Center